- Home
- OKE vs TAK Comparison
OKE vs TAK Comparison
Compare OKE & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKE
- TAK
- Stock Information
- Founded
- OKE 1906
- TAK 1781
- Country
- OKE United States
- TAK Japan
- Employees
- OKE N/A
- TAK N/A
- Industry
- OKE Oil & Gas Production
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- OKE Utilities
- TAK Health Care
- Exchange
- OKE Nasdaq
- TAK Nasdaq
- Market Cap
- OKE 47.8B
- TAK 43.3B
- IPO Year
- OKE N/A
- TAK N/A
- Fundamental
- Price
- OKE $69.75
- TAK $14.11
- Analyst Decision
- OKE Buy
- TAK
- Analyst Count
- OKE 14
- TAK 0
- Target Price
- OKE $91.14
- TAK N/A
- AVG Volume (30 Days)
- OKE 4.5M
- TAK 3.1M
- Earning Date
- OKE 10-28-2025
- TAK 10-30-2025
- Dividend Yield
- OKE 5.93%
- TAK 1.96%
- EPS Growth
- OKE 13.61
- TAK N/A
- EPS
- OKE 5.43
- TAK 0.14
- Revenue
- OKE $31,564,000,000.00
- TAK $29,846,840,032.00
- Revenue This Year
- OKE $51.79
- TAK $0.01
- Revenue Next Year
- OKE $7.49
- TAK $0.49
- P/E Ratio
- OKE $12.79
- TAK $100.98
- Revenue Growth
- OKE 58.35
- TAK N/A
- 52 Week Low
- OKE $64.02
- TAK $12.80
- 52 Week High
- OKE $118.07
- TAK $15.69
- Technical
- Relative Strength Index (RSI)
- OKE 53.11
- TAK 53.07
- Support Level
- OKE $68.42
- TAK $13.50
- Resistance Level
- OKE $70.88
- TAK $14.41
- Average True Range (ATR)
- OKE 1.56
- TAK 0.17
- MACD
- OKE 0.49
- TAK 0.09
- Stochastic Oscillator
- OKE 82.94
- TAK 78.87
About OKE ONEOK Inc.
Oneok is a diversified midstream service provider specializing in natural gas gathering, processing, storage, and transportation and natural gas liquids transportation and fractionation. It also operates a refined product and crude oil segment connecting producers, refiners, and consumers. Operations are in the midcontinent, Permian, and Rocky Mountain regions.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.